title: From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
abstract: BACKGROUND
  Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects.
  
  
  METHODS
  In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM.
  
  
  CONCLUSIONS
  There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.
authors: Indiana University School of Medicine, Division of Hematology and Oncology, Department of Medicine, Indianapolis, IN 46202, USA.
authors: Shuhong
authors: S
authors: Zhang
authors: Sherif S
authors: SS
authors: Farag